The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/156875

Please be advised that this information was generated on 2017-07-25 and may be subject to change.
An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers


* Correspondence: david.cox@lyon.unicancer.fr
Deceased
1INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France
2Université de Lyon, 69000 Lyon, France
Full list of author information is available at the end of the article

© 2015 Blein et al; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction

Breast cancer is a multifactorial disease with genetic, lifestyle and environmental susceptibility factors. Approximately 15% to 20% of the familial aggregation of breast cancer is accounted for by mutations in high-penetrance susceptibility genes [1-3], such as BRCA1 and BRCA2. Pathogenic mutations in BRCA1 and BRCA2 confer lifetime breast cancer risk of 60% to 85% [4,5] and 40% to 85% [4,5], respectively. Other genomic variations (for example, in genes encoding proteins interacting with BRCA1 and BRCA2) have been identified as modifiers of breast cancer risk and increase or decrease the risk initially conferred by BRCA1 or BRCA2 mutation [6].

BRCA1 and BRCA2 are involved in DNA repair mechanisms, including double-strand break (DSB) repair by homologous recombination [7,8]. DSBs are considered to be among the most deleterious forms of DNA damage because the integrity of both DNA strands is compromised simultaneously. These breaks can lead to genomic instability resulting in translocations, deletions, duplications or mutations when not correctly repaired [9]. Reactive oxygen species (ROS) are one of the main causes of DSBs, along with exposure to ionizing radiation, various chemical agents and ultraviolet light [10].

ROS are naturally occurring chemical derivatives of metabolism. Elevated levels of ROS and downregulation of ROS scavengers and/or antioxidant enzymes can lead to oxidative stress, which is associated with a number of human diseases, including various cancers [11]. The electron transport chain process, which takes place in the mitochondria, generates the majority of ROS in human cells. Variations in the mitochondrial genome have been shown to be associated with metabolic phenotypes and...
mitochondrial dysfunction recently was shown to promote breast cancer cell migration and invasion through the accumulation of a transcription factor, hypoxia-inducible factor 1α, via increased production of ROS [13].

Human mitochondrial DNA (mtDNA) has undergone a large number of mutations that have segregated during evolution. Those changes are now used to define mitochondrial haplogroups. Some of these changes slightly modify metabolic performance and energy production; thus, not all haplogroups have identical metabolic capacities [14]. It has been hypothesized that the geographic distribution of mitochondrial haplogroups results from selection of metabolic capacities driven mainly by adaptation to climate and nutrition [15,16].

Mitochondrial haplogroups have been associated with diverse multifactorial diseases, such as Alzheimer’s disease [17], hypertrophic cardiomyopathy [18], retinal diseases [19] or age-related macular degeneration [20]. Variations in mtDNA have also been linked to several types of cancer, such as gastric cancer [21] or renal cell carcinoma [22]. Interestingly, variations in mtDNA have been linked to several types of female cancers, including endometrial [23], ovarian [24] and breast cancer [25,26]. A recent study underlined the possibility that mtDNA might be involved in the pathogenic and molecular mechanisms of familial breast cancer [27].

The Collaborative Oncological Gene-environment Study (COGS) is a European project designed to improve understanding of genetic susceptibility to breast, ovarian and prostate cancer. This project involves several consortia: the Breast Cancer Association Consortium (BCAC) [29], the Ovarian Cancer Association Consortium [30], the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome (PRACTICAL) [31] and the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) [32]. CIMBA is a collaborative group of researchers working on genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers. As part of the COGS project, more than 200,000 single-nucleotide polymorphisms (SNPs) were genotyped for BRCA1 and BRCA2 female mutation carriers on the iCOGS chip, including 129 mitochondrial polymorphisms. The iCOGS chip is a custom Illumina™ Infinium genotyping array (Illumina, San Diego, CA, USA) designed to test, in a cost-effective manner, genetic variants related to breast, ovarian and prostate cancers.

In this study, we explored mitochondrial haplogroups as potential modifiers of breast cancer risk in women carrying pathogenic BRCA1 or BRCA2 mutations. Our study includes females diagnosed with breast cancer and unaffected carriers belonging to CIMBA. We used an original analytic phylogenetics-based approach implemented in a homemade algorithm and in the program ALTtree [33,34] to infer haplogroups and to detect associations between haplogroups and breast cancer risk.

Methods

Ethics statement

A signed informed written consent form was obtained from all participants. All contributing studies involved in CIMBA received approvals from the institutional review committees at their host institutions. Ethical committees that approved access to the data analyzed in this study are listed in Additional file 1.

BRCA1 and BRCA2 mutation carriers

Final analyses included 7,432 breast cancer cases and 7,104 unaffected BRCA1 mutation carriers, as well as 3,989 invasive breast cancer and 3,689 unaffected BRCA2 mutation carriers, all belonging to CIMBA. Supplementary specifications regarding inclusion profiles and studies belonging to CIMBA are available in the reports by Couch et al. [35] and Gaudet et al. [36]. All analyses were conducted separately on CIMBA BRCA1 and BRCA2 mutation carriers (abbreviated pop1 and pop2, respectively). Eligible female carriers were aged 18 years or older and had a pathogenic mutation in BRCA1 and/or BRCA2. Women with both BRCA1 and BRCA2 mutations were included in downstream analyses. Data were available for year of birth, age at study recruitment, age at cancer diagnosis, breast cancer diagnosis, age at cancer diagnosis, BRCA1 and BRCA2 mutation description and self-reported ethnicity. Women with ovarian cancer history were not excluded from analyses, and they represented 15% and 7% of BRCA1 and BRCA2 mutation carriers, respectively. Information regarding mastectomy was incomplete and was therefore not used as an inclusion or exclusion parameter.

Genotyping and quality filtering

Genotyping was conducted using the iCOGS custom Illumina Infinium array. Data from this array are available to the scientific community upon request. Please see [37] for more information. Genotypes were called using Illumina’s proprietary GenCall algorithm. Genotyping and quality filtering were described previously [35,36]. Initially, 129 mitochondrial SNPs were genotyped for both BRCA1 and BRCA2 mutation carriers. SNPs fulfilling the following criteria were excluded from downstream analyses: monoallelic SNPs (minor allele frequency = 0), SNPs with more than 5% data missing, annotated as triallelic, or having probes cross-matching with the nuclear genome. Heterozygous genotypes were removed from analyses, and we further filtered out SNPs having more than 5% of heterozygous calls to limit the potential for heteroplasy affecting our results. We also did not retain SNPs representing private mutations. These mutations are rare, often restricted to a few families, and not sufficiently prevalent in the general population to be included in the reference
mitochondrial evolutionary tree (see below). This last step of filtration yielded 93 and 92 SNPs for the pop1 and pop2 analyses, respectively (see Additional file 2). Only individuals with fully defined haplotypes (that is, non-missing genotypes for the 93 and 92 SNPs selected for pop1 and pop2, respectively) were included in downstream analyses (14,536 and 7,678 individuals, respectively).

Mitochondrial genome evolution and haplogroup definition
Analyses were based on the theoretical reconstructed phylogenetic tree of the mitochondrial genome (mtTree) known as PhyloTree [38] (v.15). The mtTree is rooted by the Reconstructed Sapiens Reference Sequence (RSRS). RSRS has been identified as the most likely candidate to root the mtTree by refining human mitochondrial phylogeny by parsimony [39]. Each haplogroup in mtTree is defined by the set of mtDNA SNPs that have segregated in RSRS until today in the mitochondrial genome. Each haplogroup is fully characterized by the 16,569-bp sequence resulting from the application of all the substitutions that are encoded by the corresponding SNPs in the RSRS sequence.

Haplogroups imputation
The phylogenetic approach used to infer haplogroups is described in Figure 1. Mitochondrial genome sequences can be reconstructed at each node of mtTree, given the

---

**Figure 1** Simplified representation of the phylogenetic method used to infer haplogroups. (a) Full-length haplotypic sequences are reconstructed at each node of the reference tree. (b) Haplotypes are then restricted to available loci. Sequences of the same color are identical. (c) Unique short haplotypes are matched directly with the corresponding haplogroup. (d) Sequences that match with several haplogroups are associated with their most recent common ancestor haplogroup. RSRS, Reconstructed Sapiens Reference Sequence.
substitutions that have segregated in RSRS. Each haplotype therefore has a corresponding full-length mitochondrial sequence. However, the full-length mitochondrial sequence is not available in the data, because the iCOGS platform captured only 93 and 92 SNPs for pop1 and pop2, respectively. Thus, for each of the 7,864 nodes of the phylogenetic tree, the corresponding short haplotype (that is, the full-length sequence restricted to available loci) was defined. Some of the short haplotypes are unique, and they can be matched with their corresponding haplogroup directly. However, most of the time, given the small number of SNPs analyzed, several haplogroups correspond to the same short haplotype. Consequently, a unique haplogroup cannot confidently be assigned to each short haplotype. Therefore, each short haplotype was assigned the most recent common ancestor of all the haplogroups that share the same short haplotype. Once this matching was done, short haplotypes were reconstructed in the same way for each individual in our dataset and were assigned the corresponding haplogroup. The accuracy of the method used was assessed by application to a set of 630 mtDNA sequences of known European and Caucasian haplogroups (see Additional file 3).

Association detection
This phylogenetic approach is based on the identification of subclades in the reference phylogenetic tree of the mitochondrial genome differentially enriched for cases and unaffected controls compared with neighboring subclades. We used ALTTree [33,34] to perform association testing. ALTTree—standing for Association detection and Localization of susceptibility sites using haplotype phylogenetic Trees—is an algorithm used to perform nested homogeneity tests to compare distributions of affected and unaffected individuals in the different clades of a given phylogenetic tree. The objective is to detect if some clades of a phylogenetic tree are more or less enriched in affected or unaffected individuals compared with the rest of the tree. There are as many tests performed as there are levels in the phylogenetic tree. The \( P \)-value at each level of the tree is obtained by a permutation procedure in which 1,000 permutations are performed. Individual labels ("affected" or "unaffected") are permuted 1,000 times to see to what extent the observed distribution of affected or unaffected is different from a random distribution. A procedure to correct for multiple testing adapted to nested tests [40] is implemented in ALTTree. The objective of ALTTree is to detect an enrichment difference at the level of the whole tree. To conserve computational time and resources, only the most significant \( P \)-value obtained for all tests performed on one tree is corrected.

Handling genetic dependency
ALTTree is used to perform homogeneity tests to detect differences in enrichment or depletion of affected or unaffected individuals between clades in the phylogenetic tree. This kind of test can be performed only on independent data. However, because some individuals in the CIMBA dataset belong to the same family, we constructed datasets with genetically independent data by randomly selecting one individual from among all those belonging to the same family and sharing the same short haplotype. To take into account the full variability of our data, we resampled 1,000 times. The results of the analysis pipeline are obtained for each resampling independently and then averaged over the 1,000 resamplings to obtain final results.

Character reconstruction at ancestral nodes
Before the ALTTree localization algorithm was launched, ancestral sequences were reconstructed at each internal tree node; that is, short haplotypes were inferred with maximum likelihood at all nodes that were not leaves. We used the software PAML [41] to perform the reconstruction at ancestral nodes using a maximum likelihood method. The phylogeny model used was the general time-reversible model (either GTR or REV).

Localization of susceptibility sites
ALTTree also includes an algorithm used to identify which sites are the most likely ones to be involved in the association detected. For each short haplotype observed, the ALTTree add-on altree-add-S adds to the short haplotype sequence a supplementary character called \( S \), which represents the disease status associated with this short haplotype. Are individuals carrying this short haplotype more often affected or unaffected? \( S \) is calculated based on the affected and unaffected counts, the relative proportion of affected and unaffected in the whole dataset, and sensibility parameter \( e \). \( e \) was set to its default value, which is 1. After \( S \) character computation, haplotypes including character \( S \) are reconstructed at ancestral nodes. Susceptibility site localization is achieved with ALTTree by computing a correlated evolution index calculated between each change of each site and the changes of the character \( S \) in the two possible directions of change. The sites whose evolution are the most correlated with the character \( S \) are the most likely susceptibility sites.

Selected subclades
The analyses were carried out on the full evolutionary tree. However, the more haplogroups there are at each level, the less statistical power homogeneity tests have. Therefore, analyses were also applied to subclades extracted from the tree. Subclades were defined using counts of individuals in each haplogroup of the clade to maximize statistical power. The chosen subclades
and corresponding affected and unaffected counts are presented in Table 2.

**Statistical analysis**

We quantified the effect associated with enrichment discovered by applying ALTree by building a weighted Cox regression in which the outcome variable is the status (affected or non-affected) and the explicative variable is the inferred haplogroup. Analyses were stratified by country. Data were restricted to the clades of interest. The uncertainty in haplogroup inference was not taken into account in the model. The weighting method used takes into account breast cancer incidence rate as a function of age [42] and the gene containing the observed pathogenic mutation (that is, BRCA1 or BRCA2). Familial dependency was handled by using a robust sandwich estimate of variance (R package survival, cluster() function).

**Results**

**Haplogroup imputation**

In Additional file 4, absolute and relative frequencies are recapitulated for each haplogroup imputed in BRCA1 and BRCA2 mutation carriers. For BRCA1 mutation carriers, we reconstructed 489 distinct short haplotypes of 93 loci from the genotypes data. Only 162 of those 489 short haplotypes matched theoretical haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 162 haplotypes represented 13,315 of 14,536 individuals. Thus, 91.6% of BRCA1 mutation carriers were successfully assigned a haplogroup. For BRCA2 mutation carriers, we reconstructed 350 distinct short haplotypes of 92 loci from our genotype data. Only 139 of those 350 short haplotypes matched theoretical haplotypes reconstructed in the reference mitochondrial evolutionary tree. These 139 haplotypes represented 6,996 of 7,678 individuals. Thus, 91.1% of BRCA2 mutation carriers were successfully assigned a haplogroup. Because more BRCA1 than BRCA2 mutation carriers were genotyped (14,536 vs. 7,678 individuals), we logically observed more distinct haplotypes in pop1 than in pop2 (489 vs. 350 haplotypes).

The accuracy of the main haplogroup inference method used was estimated at 82% and reached 100% for haplogroups I, J, K, T, U, W and X. Given the set of SNPs we disposed of, our method has difficulty differentiating between H and V haplogroups (see Additional file 3).

**Association results**

For both populations of BRCA1 or BRCA2 mutation carriers, as well as for the full tree as for all selected subclades (see Table 1), we extracted the mean corrected P-values for association testing over all resamplings performed (see Table 2). The only corrected P-value that remained significant was that obtained for subclade T (abbreviated T⁰) in the population of individuals of BRCA2 mutation carriers (P = 0.04).

The phylogenetic tree of subclade T (see Figure 2a) contains only three levels; thus, only three tests were performed within this clade. Raw P-values were examined to determine at which level of the tree ALTree detects a difference of enrichment in affected or unaffected individuals (see Table 3). Only the P-value associated with the test performed at the first level of the tree is significant. We looked more closely at the mean frequencies of affected and unaffected individuals in the tree at this level (see Figure 2b). In the T1a1 subclade, the mean count of affected and unaffected are 32 and 47, respectively. In the T2⁺ subclade, we observed, on average, 217 and 148 affected and unaffected individuals, respectively, whereas in the T subclade, we observed, on average, 13 and 11 affected and unaffected individuals, respectively. The ranges observed for each of these values over the 1,000 resamplings are represented in Figure 2b. On the basis of these observations, we conclude that subclade T1a1 is depleted in affected carriers compared with the neighboring subclades T and T2.

---

<table>
<thead>
<tr>
<th>Table 1 Counts of participants in selected subclades</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subclade</strong></td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>U8</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>J</td>
</tr>
<tr>
<td>J1</td>
</tr>
<tr>
<td>H</td>
</tr>
<tr>
<td>H1</td>
</tr>
<tr>
<td>U5</td>
</tr>
<tr>
<td>X1'T*3</td>
</tr>
<tr>
<td>K1a</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 2 Mean corrected P-values for association testing with ALTree</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Subclade</strong></td>
</tr>
<tr>
<td>------------</td>
</tr>
<tr>
<td>Full</td>
</tr>
<tr>
<td>U8</td>
</tr>
<tr>
<td>T</td>
</tr>
<tr>
<td>J</td>
</tr>
<tr>
<td>J1</td>
</tr>
<tr>
<td>H</td>
</tr>
<tr>
<td>H1</td>
</tr>
<tr>
<td>U5</td>
</tr>
<tr>
<td>X1'T*3</td>
</tr>
<tr>
<td>K1a</td>
</tr>
</tbody>
</table>

*pop1, BRCA1 mutation carrier; pop2, BRCA2 mutation carrier. Bold indicates a significant P-value.*
Localization results
We performed a localization analysis with ALTree. The correlated evolution index for all non-monomorphic sites observed in short haplotype sequences of subclade T are displayed in Additional file 5. The higher the correlated evolution index, the more likely it is that corresponding sites will be involved in the observed association.

Three short haplotype sites numbered 44, 57 and 72 and corresponding to SNPs T988C, G11812A/rs4154217 and G13708A/rs28359178, respectively, clearly distinguish themselves, with correlation index values of 0.390, 0.324 and 0.318, respectively, whereas the correlation index values of all other sites ranged from −0.270 to −0.101.

Table 4 shows the details for these three loci.

Effect quantification
The ALTree method is able to detect an association, but cannot to quantify the associated effect. We estimated the risk of breast cancer for individuals with the T1a1 haplogroup compared with individuals with another T subclade haplogroup in the population of BRCA2 mutation carriers using a more classical statistical method, a weighted Cox regression. We found a breast cancer HR of 0.55 (95% CI, 0.34 to 0.88; P = 0.014). We also tested haplogroup T1a1 and compared it with other T* haplogroups and the H haplogroup (the main haplogroup in the general population), and we found a breast cancer HR of 0.62 (95% CI, 0.40 to 0.95; P = 0.03).

Discussion
We employed an original phylogenetic analytic method, coupled with more classical molecular epidemiologic analyses, to detect mitochondrial haplogroups differentially enriched for affected BRCA1/2 mutation carriers. We successfully inferred haplogroups for more than 90% of individuals in our dataset. After haplogroup imputation, the ALTree method identified T1a1 in the T clade as differentially enriched in affected BRCA2 mutation carriers, whereas no enrichment difference was found for BRCA1 mutation carriers. The T subclade is present in 4% of African populations compared with 11% in Caucasian and Eastern European populations [43]. In our data, the T subclade represented 9.34% of BRCA1 mutation carriers and 9.30% of BRCA2 carriers. The ALTree method also identified three potential breast cancer susceptibility loci in mtDNA. The main goals of using the phylogenetic method we used were to improve statistical power by regrouping subclades according to genetic considerations, to limit the number of tests performed and to precisely quantify this number. ALTree identified three SNPs of interest. Whereas the association we observed could possibly be driven by a single SNP, no difference was observed between multivariate and univariate cox models including the three SNPs identified by ALTree (data not shown).

In this study, we investigated to what extent mtDNA variability modified breast cancer risk in individuals...
Table 4 Description of loci identified as potential susceptibility sites by ALTree

<table>
<thead>
<tr>
<th>Site</th>
<th>SNP name</th>
<th>Position</th>
<th>Direction of change</th>
<th>Correlated evolution index</th>
<th>Major allele</th>
<th>Minor allele</th>
<th>MAF in pop2</th>
</tr>
</thead>
<tbody>
<tr>
<td>44</td>
<td>Mitto19900C</td>
<td>9,899</td>
<td>T → C</td>
<td>0.390</td>
<td>T</td>
<td>C</td>
<td>0.016</td>
</tr>
<tr>
<td>57</td>
<td>rs41544217</td>
<td>11,812</td>
<td>G → A</td>
<td>0.324</td>
<td>A</td>
<td>G</td>
<td>0.071</td>
</tr>
<tr>
<td>72</td>
<td>rs28359178</td>
<td>13,708</td>
<td>G → A</td>
<td>0.318</td>
<td>G</td>
<td>A</td>
<td>0.111</td>
</tr>
</tbody>
</table>

*MAF, Mean allele frequency; pop2, BRCA2 mutation carrier.

Table 4 Description of loci identified as potential susceptibility sites by ALTree

- **BRCA1/2:** A large proportion of breast cancer heritability still remains unexplained today [44]. Different methods exist to study genomic susceptibility to a disease, such as linkage analyses (which identified the **BRCA1** and **BRCA2** susceptibility genes) or genome-wide association studies (GWASs). However, classical linkage analysis cannot be applied to the haploid mitochondrial genome. Furthermore, commercial GWAS chips available do not adequately capture the majority of mtDNA SNPs. A non-genome-wide and mtDNA-focused approach was required to explore how mtDNA variability influences breast cancer risk. Here we have shown that **BRCA2** mutation carriers with the subclade T1a1 have between 30% and 50% less risk of breast cancer than those with other clades, which, if validated, is a clinically meaningful risk reduction and may influence the choice of risk management strategies.

The association we observed among **BRCA2**, but not **BRCA1**, mutation carriers may reveal a functional alteration that would be specific to mechanisms involving **BRCA2**-related breast cancer. Today, it is established that **BRCA1**- and **BRCA2**-associated breast cancers are not phenotypically identical. These two types of tumors do not harbor the same gene expression profiles or copy number alterations [45]. Breast cancer risk modifiers in **BRCA1/2** mutation carriers have already been identified [46]. However, most of them are specific from one or the other type of mutation carried [47]. It is therefore not surprising that this observation is observed in **BRCA2** mutation carriers only.

Our inability to assign haplogroups to 9% of study participants could have three main explanations. First, given the high mutation rate in the mitochondrial genome, observed combinations of mtDNA SNPs might have appeared relatively recently in the general population, and the corresponding haplotypes might not yet be incorporated into PhyloTree. Second, only one genotyping error could lead to chimeric haplotypes that do not exist, although, given the quality of our genotyping data, this is unlikely. Third, the mitochondrial reference evolutionary tree PhyloTree is based on phylogeny reconstruction by parsimony, and, for some subclades, it might be suboptimal, especially for haplogroups relying on few mitochondrial sequences, as is the case for African haplogroups [48]. In cases of uncertainty, the choice we made to assign the most recent common ancestor to the studied haplotype enabled us to improve statistical power without introducing a bias in the detected association. For the association detected between T, T1*, and T2* subclades, the haplogroup inference method used did not bias the counts of affected and unaffected individuals in these subclades. More details are presented in Additional file 6. Furthermore, on the basis of the haplogroup inference with our method of 630 European and Caucasian mtDNA sequences whose haplogroup is known, we successfully assigned the correct main haplogroup and subhaplogroup of 100% of sequences belonging to T, T2*, and T1a1* haplogroups.

We quantified the effect corresponding to the detected association by using a more classical approach. We built a weighted Cox regression including inferred haplogroup as an explicative variable. However, the uncertainty in haplogroup inference was not taken into account in this model. Nevertheless, based on haplogroup assignment and regrouping performed in clade T, affected and unaffected counts of individuals in this clade were not biased.

With only 129 loci genotyped over the 16,569 nucleotides composing the mitochondrial genome, we certainly did not explore the full variability of mitochondrial haplotypes. A characterization of individual mitochondrial genomes would require more complete data acquisition methods to be used, such as next-generation sequencing. However, next-generation sequencing has its own limits and challenges, because some regions of the mitochondrial genome are not easily mappable, owing to a high homology with the nuclear genome, among other factors, and important bioinformatics treatment is necessary to overcome sequencing technology biases. Finally, even for a relatively short genome of “only” 16,569 bp, mtDNA sequencing of more than 20,000 individuals would represent a major increase in cost relative to genotyping 129 SNPs.

**ALTree** identified T9899C, G11812A/rs41544217 and G13708A/rs28359178 as three potential susceptibility sites for the discovered association (see Additional file 7). These three SNPs are located in the coding part of genes **MT-C03**, **MT-ND4**, and **MT-ND5**, respectively. When looking at PhyloTree, T9899C seems to be involved in T1 subclade definition, whereas G13708A and A11812G are involved in T2 subclade definition. Whereas T98899C and
G11821/rs41544217 are synonymous SNPs, G10398A leads to a change of amino acid in the final protein (from alanine to threonine). These two synonymous SNPs have never been described in a disease context in the literature. G13708A is also known for being a secondary mutation for Leber’s hereditary optic neuropathy (LHON) and multiple sclerosis [49]. Although the role of secondary mutations in LHON is still controversial, G13708A could be associated with impairment of the respiratory chain in this pathology. G13708A has also been described as a somatic mutation in a breast cancer tumor, whereas it was not present in adjacent normal tissue or in blood leukocytes [50]. A high proportion of mitochondrial somatic tumor-specific variants are also known mtDNA SNPs, which is consistent with the hypothesis that tumor cells are prone to acquire the same mutations that segregate into mtDNA by selective adaptation when humans migrated out of Africa and confronted new environments [51]. Interestingly, the germline variant G13708A has already been shown to be inversely associated with familial breast cancer risk (with the same direction of the association), with a breast cancer odds ratio of 0.47 (95% CI, 0.24 to 0.92) [52]. None of these SNPs have been described in the context of ovarian cancer.

The corrected P-value obtained using ALTree in studying clade T is 0.02, which is not highly significant. A replication step should be performed to validate these results. However, it will be difficult to include enough women in this replication step, given the specific profile studied here. In fact, the estimations of BRCA2 pathogenic mutations in the general population range from 0.068% [5] to 0.69% [53]. T1a1 represents only a small percentage of European haplogroups (from 1% to 2%). The number of women who have this association is therefore low. However, women carrying such mutations are confronted with drastic choices regarding the prevention of breast cancer, notably prophylactic mastectomy or complete hysterectomy. If breast cancer risk is really reduced by a factor of 2 for women with T1a1, this could be an important fact to take into account for breast cancer prevention.

Conclusions

This study and our results suggest that mitochondrial haplogroup T1a1 may modify the individual breast cancer risk in BRCA2 mutation carriers. For now, this observation cannot be extended to the general population. Further investigation of the biological mechanism behind the associations we observed may further reinforce the hypothesis that the mitochondrial genome is influential in breast cancer risk, particularly among carriers of BRCA2 mutations, and, if validated, is of a level to influence cancer risk management choices.
members of and participants in the Ontario Familial Breast Cancer Registry for their contributions to the study; Vilus Rudatis, Laimonas Grilevičius, Drs Janis Egilis, Anna Kritova and Aivars Stengrevics; the families who contribute to the BRCA-gene mutations and breast cancer in South African women (BMBSA) study; Chun Ding and Linda Steele; Alicia Barroso, Rosario Alonso, Guillermo Pita, Alessandra Viel and Laura delia Puppa of the Centro di Riferimento Oncologico, IRCCS, Aviano (PN), Italy; Laura Papi of the University of Florence, Florence, Italy; Monica Barile of the Istituto di Epidemiologia di Oncologia, Milan, Italy; Liliana Varesco of the IRCCS AOU San Martino – IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy; Stefania Tommasi, Brunella Pilato and Rossanna Lambo of the Istituto Nazionale Tumori “Giovanni Paolo II” – Bari, Italy; Aline Martayan of the Istituto Nazionale Tumori Regina Bena, Rome, Italy; Maria Grazia Tibelliti of the Ospedale di Circolo-Università dell’Insurbia, Varese, Italy; and the personnel of the Cogentech Cancer Genetic Test Laboratory, Milan, Italy.

**Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE)**

Collaborating Centers: coordinating center, Cambridge, UK: Debra Frost, Steve Ellis, Elena Fineberg and Radka Platte; North of Scotland Regional Genetic Service, Edinburgh, UK: Trevor Cole, Kai-rei Ong and Jonathan Hoffman; South West Regional Genetics Service, Bristol, UK: Alan Donaldson and Margaret James; East Anglian Regional Genetics Service, Cambridge, UK: Marc Tischkowitz, Joan Paterson and Amy Taylor; Medical Genetics Service, Cardiff, UK: Alexandra Murray, Mark T Rogers and Emma McCann; St James’s Hospital, Dublin, and National Centre for Medical Genetics, Dublin, Ireland: M John Kennedy and David Barton; South East of Scotland Regional Genetics Service, Edinburgh, UK: Mary Porteous and Sarah Drummond; Peninsula Clinical Genetics Service, Exeter, UK: Carol Beever, Emma Kivuva, Anne Seare, Selina Goodman and Kathryn Hill; West of Scotland Regional Genetics Service, Glasgow, UK: Rosemary Davidson, Victoria Murray, Nicole Bradshaw, Lesley Snadder, Mark Longmuir, Catherine Watt, Sarah Gibson, Elisha Haque, Ed Tobias and Alexis Duncan; South East Thames Regional Genetics Service, Guy’s Hospital London: Louise Izatt, Chris Jacobs and Caroline Langman; North West Thames Regional Genetics Service, Harrow, UK: Huw Dorkins; Leicesterhire Clinical Genetics Service, Leicestershire, UK: Julian Banwell; Yorkshire Regional Genetics Service, Leeds, UK: Julian Adlaad and Gemma Serra-Fellu; Cheshire & Merseyside Clinical Genetics Service, Liverpool, UK: Ian Ellis and Catherine Houghton; Manchester Regional Genetics Service, Manchester, UK: D Gareth Evans, Fiona Laloo and Jane Taylor; North East Thames Regional Genetics Service, NE Thames, London: Lucy Side, Alan Male and Cheryl Berlin; Nottingham Centre for Medical Genetics, Nottingham, UK: Jacqueline Eason and Rebecca Collier; Northern Clinical Genetics Service, Newcastle, UK: Fiona Douglas, Oonaugh Clabber and Irene Jobson; Oxford Regional Genetics Service, Oxford, UK: Lisa Walker, Diane McLeod, Dorothy Halliday, Sarah Durell and Barbara Stayner; The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London: Ross Eeles, Susan Shanley, Nazneen Rahman, Richard Houlston, Elizabeth Bancroft, Elizabeth Page, Audrey Ardem-Jones, Kelly Kohut, Jennifer Wiggins, Elena Castro, Emma Killick, Sue Martin, Gillian Rea and Anjana Kulkarni; North Trent Clinical Genetics Service, Sheffield, UK: Jackie Cook, Oliver Quarrall and Cathryn Bardsley; South West Thames Regional Genetics Service, London: Shirley Hodgson, Sheila Goff, Glen Brice, Lizze Winchester, Charlotte Eddy, Vishakha Tripathi, Virginia Attard and Anna Lehmann; Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK: Diana Eccles, Annette Lister, Cally Crawford, Donna Midbry and Sarah Smallley; and Jollene Weaver and Dr Betsy Bove for their technical support.

**Genetic Modifiers of Cancer Risk in BRCA1/2 mutation Carriers (GEMO)**

Study: National Cancer Genetics Network (NCGEN) conducted in 16 centers in the UK: The Breast Cancer Epidemiology Consortium (BCEC) and the Celtic Breast Cancer Group (CBCG); The European Breast Cancer Cooperative (EBCC); The Breast Cancer Intergroup (BCI); The Breast Cancer Collaborative Group (BCCG); The Breast Cancer International Research Group (BCIRG); The Breast Cancer Family Registry (BCFR); The Breast Cancer Genetic Consortium (BCGC); The Breast Cancer Gene Consortium (BCGC); The Breast Cancer Group (BCG); The Breast Cancer International Research Group (BCIRG); The Breast Cancer Intergroup (BCI); The Breast Cancer Collaborative Group (BCCG); The Breast Cancer International Research Group (BCIRG); The Breast Cancer Group (BCG); The Breast Cancer Gene Consortium (BCGC); The Breast Cancer Intergroup (BCI); The Breast Cancer Collaborative Group (BCCG); The Breast Cancer International Research Group (BCIRG); The Breast Cancer Group (BCG); The Breast Cancer Gene Consortium (BCGC); The Breast Cancer Intergroup (BCI); The Breast Cancer Collaborative Group (BCCG). The study was supported by the European Union (FP6 LSHC-2005-518190), the National Breast Cancer Coalition (NBCF), the National Cancer Institute (NCI) and the Breast Cancer Research Foundation (BCRF). The study was also supported by grants from the Department of Health and the National Cancer Institute (NIH), the National Breast Cancer Coalition (NBCF), the National Cancer Institute (NCI) and the Breast Cancer Research Foundation (BCRF). The study was also supported by grants from the Department of Health and the National Cancer Institute (NIH), the National Breast Cancer Coalition (NBCF), the National Cancer Institute (NCI) and the Breast Cancer Research Foundation (BCRF).
Czech Republic); Michal Zikan, Petr Pohlereich and Zdenek Kleibl (Oncogenecologic Center and Department of Biochemistry and Experimental Oncology, First Faculty of Medicine, Charles University, Prague, Czech Republic); Anne Lincoln and Lauren Jacobs; the National Israeli Cancer Control Center (NICC) National Familial Cancer Consultation Service team led by Sara Dishon; the laboratory team led by Dr Flavio Leblékovicz; and the research field operations team led by Ma Pinchev; members and participants in the Ontario Cancer Genetics Network for their contributions to the study. Leigha Senter, Kevin Sweet, Caroline Caven and Michelle O’Connor were instrumental in accrual of study participants, assortment of medical records and database management; The Ohio State University Human Genetics Sample Bank; the Merav Breast Center team at the Sheba Medical Center, Åke Borg, Håkan Olsson, Helena Jerntorp, Karin Henriksson, Katja Harbost, Maria Soller and Ulf Krotoforsen; Sahlgrenska University Hospital, Gothenburg, Sweden; Anna Överholm, Margareta Nordling, Per Karlsson and Zakaria Einberg; Stockholm and Karolinska University Hospital, Stockholm; Anna von Wachenfeldt, Annelie Liljegren, Annika Lindblom, Brita Arver, Gisela Barbany Bustrizia and Johanna Rantala; Umeå University Hospital, Umeå, Sweden; Beatrice Melin, Christina Edwindsdotter Ardor and Monica Emanuelsson; Uppsala University, Uppsala, Sweden; Brigitte Lemon, Martina Hellstrom Piggy and Bernard Rosenquist; Linköping University Hospital, Linköping, Sweden; Marie Stenmark-Aksamîl and Sigrun Liedgren; Cecilia Zvocer, Qun Niu, and physicians, genetic counselors, research nurses and staff of the Comprehensive Cancer Risk and Prevention Clinic of University of Chicago Medicine, Chicago, IL, USA, for their contributions to this resource; Joyce Seldon, MSGC, and Lorna Rivan, MPH; Dr Robert Nussbaum and the following genetic counselors: Beth Crawford, Kate Loranger, Julie Mak, Nicola Stewart, Robin Lee, Annie Blanco and Peggy Conrad; Salina Chan; Paul DP Pharoah, Simon Gayther, Susan Ramus, Carole Pye, Patricia Harrington and Eva Wozniak for their contributions to the UK Familial Ovarian Cancer Registry (UFOCR); Geoffrey Lindeman, Marion Harris, Martin Delatycki of the Victorian Familial Cancer Trials Group; and Sarah Sawyer, Rebecca Dieissen and Ella Thompson.

**Funding**

**Higher-level funding:** The COGS project is funded through a European Commission Seventh Framework Program grant (agreement number 223175: HEALTH-F2-2009-223175). The COGBA data management and data analysis were supported by Cancer Research UK grants C12292/A11174 and C1287/A10118. SH is supported by a National Health and Medical Research Council (NHMRC) program grant (to GCT).

**Individual researcher support:** ACA is a Cancer Research UK Senior Cancer Research Fellow (C12292/A11174). DFE is a Principal Research Fellow of Cancer Research UK. GC, MTS and IC are supported by the National Health and Medical Research Council (NHMRC). BK holds an American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN). MHG and PLM were supported by funding from the Intramural Research Program of the National Cancer Institute, National Institutes of Health. OIO is an American Cancer Society Clinical Research Professor. JS is Chairholder of the Canada Research Chair in Oncogenetics.

**Funding of constituent studies:** The Breast Cancer Family Registry (BCFR) was supported by grant UM1 CA164920 from the National Cancer Institute, National Institutes of Health. The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government or the BCFR. The Baltic Familial Breast Ovarian Cancer Consortium (BFBOCC) is partly supported by Lithuania (BFBOCC-LT): Research Council of Lithuania grant LG1-07/2012; BFBOCC-LV (Latvia) is partly supported by LSC grant 10.0010.08 and in part by a grant from the European Social Fund number 2009/0220/1DP/1.1.1.2.0/09/AIPA/01A/016 and the Liepāja City Council, Liepāja, Latvia; Beth Israel Deaconess Medical Center Cancer Center is supported by the Breast Cancer Research Foundation; BRCA-gene mutations and breast cancer in South African women (BMBSA) was supported by grants from the Cancer Association of South Africa (Cansa) to Elizabeth J van Rensburg; SLN (Beckman Research Institute, City of Hope, Duarte, CA, USA) was partly supported by the Morris and Horowitz Families Professorship in Cancer Biology and Outcomes Research; the Copenhagen Breast Cancer Study (CPCS) was supported by the NEYE Foundation; the Spanish National Cancer Research Center (Centro Nacional de Investigaciones Oncológicas (CNIO)) was partly supported by the Spanish Association against Cancer (Asociación Española Contra el Cáncer AECC08), Thematic Network Cooperative Research in Cancer (Red Temática Investigación Cooperativa en Cáncer (RTICC), Centro de Investigación Cáncer, Salamanca, Spain) RTICC 06/0020/1060, Spanish Ministry of Science and Innovation grants FIS PI10 1120 (Fondo de Investigación Sanitaria (FIS)) and SAF2010-20493, and the Fundación Mutua Madrileña (FMMa); the City of Hope Clinical Cancer Genetics Community Network and the Hereditary Cancer Research Registry (CON-CGCRN), supported in part by award number 5RC4A153828 (Principal Investigator: JMM) from the National Cancer Institute and the Office of the Director, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

**COSINsordi Studi Italiani sui Tumori Ereditari Alla Mammezza, Italy (CONsordi Team):** Funds from Italian citizens who allocated the "$5 \times 1,000\)^{\text{th}}$ share of their tax payment in support of the Fondazione RICCS Istituto Nazionale Tumori, according to Italian laws (Istituto Nazionale dei Tumori (INT)) institutional strategic project "$5 \times 1,000\)^{\text{th}}$ (to SM); the Italian Association for Cancer Research (AIRC) (to LO); National Centre For Scientific Research “Demokritos” has been cofinanced by the European Union (European Social Fund (ESF)) and Greek national funds through the “Education and Lifelong Learning” operational programme of the National Strategic Reference Framework (NSRF) – Research Funding Program of the General Secretariat for Research and Technology: ARISTEA; “Heracleitus II: Investing in knowledge society through the European Social Fund”; the DKFZ study was supported by the Deutsches Krebsforschungszentrum (DKFZ); Epidemiological Study of BRCA1 and BRCA2 Mutation Carriers (EMBRACE) is supported by grants: Cancer Research UK grants: C1287/A11174 and C1287/A11990; DGE and FL are supported by a National Institute for Health Research (NIHR) grant to the Biomedical Research Centre, Manchester, UK; the investigators at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London; RE and EB are supported by Cancer Research UK grant CS047/A8385; Kansas University Medical Center: The authors acknowledge support from The University of Kansas Cancer Center (P30 CA168524) and the Kansas Bioscience Authority Eminent Scholar Program; AKG was funded by grants SU01 CA113916 and R01 CA140323 and by the Challengers Distinguished Chair in Biomedical Sciences Professorship; The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by German Cancer Aid (grant 105076) (to RK) and by the Center for Molecular Medicine Cologne (CMMCC); GC-HBOC is deeply grateful to Dr Sabine Preissler-Adam for providing information and samples; the GEMO Study was supported by the Ligue Nationale contre le Cancer; the Association “Le cancer du sein, parlons-en!” Award; and the Canadian Institutes of Health Research for the CHR Team in Familial Risks of Breast Cancer program; G-FAST; KDL is supported by GOA grant BOF10/GOA/019 (Ghent University) and spearhead funding of Ghent University Hospital; the Gynecologic Oncology Group (GOG) was supported by National Cancer Institute grants to the GOG Administrative Office and Tissue Bank (grant CA 27469), the GOG Statistical and Data Center (grant CA 37517) and GOG’s Cancer Prevention and Control Committee (grant CA 101169); HSCC was supported by grants R01/200369/00016 and 12/00339 from Instituto de Salud Carlos III (ISCIII), Madrid, Spain, partially supported by European Regional Development Fund (Fonds européén de développement régional (FEDER)) funds; the Helsinki Breast Cancer Study (HEBCS) was financially supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (266528), the Finnish Cancer Society and the Sigrid Juselius Foundation; HEBON is supported by the Dutch Cancer Society grants 901999-1854, NWO204-3088 and NWO207-3756, the Netherlands Organization of Scientific Research grant NWO 11090024, the Pink Ribbon grant 110005 and Biobanking and Molecular Resource Infrastructure (BBMRI) grant NWO 184.021.017/CP46; HEBON thanks the registration teams of the Comprehensive Cancer Centre Netherlands and Comprehensive Centre South (together the Netherlands Cancer Registry) and PALGA (Dutch Pathology Registry) for part of the data collection; the High Risk Breast Cancer Program (HRBPC) is supported by the Hong Kong Hereditary Breast Cancer Family Registry and the Dr Ellen Li Charitable Foundation, Hong Kong; the Hungarian Breast and Ovarian Cancer Study (HUNBOCS) was supported by Hungarian Research and Technological Innovation Fund (KIA)/Hungarian Scientific Research Fund (Oszlánok Tudományos Kutatók Alapprogramok (OTKA)) research grants KTIA-OTKA Ck-80745 and KTIA-OTKA K-112228; Institut Català d’Oncologia (ICO): contract grant sponsor: Asociación Española Contra el Cáncer, Spanish Health Research Foundation; Ramón Areces Foundation; Instituto de Salud
Carlos III (ISCIII); Catalan Health Institute; and Autonomous Government of Catalonia; contract grant numbers ISCIII RTIC RD06/0201051, PI09/02483, PI10/01422, PI10/00748, PI13/0028S, PI13/01819 2009SGR290 and PI13/01819 2009SGR283; the International Hereditary Cancer Center (Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland) was supported by grant P30_KBN_122/P03/2004, Landsplit–The National University Hospital of Iceland was supported by the Icelandic Association “Walking for Breast Cancer Research” and by the Landsplit University Hospital Research Fund; the Interdisciplinary Health Research Internal Team Breast Cancer Susceptibility Study (INHERIT) was supported by the Canadian Institutes of Health Research (CIHR) for the “CIHR Team in Familial Risks of Breast Cancer” program, Canadian Breast Cancer Research Alliance grant O10511 and Ministry of Economic Development, Innovation and Export Trade grant PSR-SIRI-701; the Istituto Oncologico Veneto Hereditary Breast and Ovarian Cancer Study (IOVHB0CS) is supported by the Ministero della Salute and a “$ × 1,000” Istituto Oncologico Veneto grant; the Portuguese Oncology Institute–Porto Breast Cancer Study (IPOB0CS) was supported in part by Liga Portuguesa Contra o Cancer; KcnFab is supported by a grant from the National Cancer Institute; (CA116201), a US Department of Defense Ovarian Cancer Idea award (WB1XWH-10-1-0341), a grant from the Breast Cancer Research Foundation, a generous gift from the David F and Margaret T Grohne Family Foundation and the Ting Tsung and Wei Fong Chao Foundation; McGill University Jewish General Hospital Weekend to End Breast Cancer, Quebec Ministry of Economic Development, Innovation and Export Trade; Modifier Study of Quantitative Effects on Disease (MedSQuAD) was supported by the Ministry of Health of the Czech Republic to Maxaryk Memorial Cancer Institute (MH CZ – DR0) (MMC 00209805) and by the European Regional Development Fund and the State Budget of the Czech Republic (RECAMO, CZ.1.05/2.1.00/03.0101) (to LF), and by Charles University in Prague project UNCE204024 (MZ): Memorial Sloan Kettering Cancer Center (MSKCC) is supported by grants from the Breast Cancer Research Foundation and Robert and Kate Niehaus Clinical Cancer Genetics Initiative; National Cancer Institute, National Institutes of Health: The research of MHG and PLM was supported by the Intramural Research Program of the National Cancer Institute and by support services contracts N02-CP-11019-50 and N02-CP-65504 with Westat, Inc. Rockville, MD, USA; the National Israeli Cancer Control Center (NICCC) is supported by Clalit Health Services in Israel; some of its activities are supported by the Israel Cancer Association and the Breast Cancer Research Foundation (BCRF), New York, NY, USA; NN Petrov Institute of Oncology has been supported by the Russian Federation for Basic Research (grants 11-04-00227, 12-04-00928 and 12-04-01490) and the Federal Agency for Science and Innovations, Russia (contract 02.740.11.0780). The Ohio State University Clinical Cancer Genetics (OSUGCC) is supported by The Ohio State University Comprehensive Cancer Center; the Pisa Breast Cancer Study (PBCS) was supported by Istituto Toscano Tumori (ITT) grants 2011–2013; Sheba Medical Center was partially funded through a grant from the Israel Cancer Association and funding for the Israeli Inherited Breast Cancer Consortium; the Swedish Breast Cancer Study collaborators were partially supported by the Swedish Cancer Society; The University of Chicago is supported by an NCI Specialized Program of Research Excellence (SPORE) in Breast Cancer (CA125183); R01 CA142996 and 1U01CA161032 and by the Ralph and Marion Falk Medical Research Trust, the Entertainment Fund National Women’s Cancer Research Alliance and the Breast Cancer Research Foundation; University of California, Los Angeles Jonsson Comprehensive Cancer Center Foundation Breast Cancer Research Foundation; University of California, San Francisco Cancer Risk Program and Helen Diller Family Comprehensive Cancer Center; UK Familial Ovarian Cancer Registry (UKFOCR) was supported by a project grant from Cancer Research UK (to Paul DP Pharoah); the University of Pennsylvania: National Institutes of Health (NIH) grants R01 CA102776 and R01 CA083855; the Breast Cancer Research Foundation; the Susan G Komen for the Cure, Basser Center for BRCA; Victorian Familial Cancer Trials Group (VFCTG): Victorian Cancer Agency, Cancer Australia, National Breast Cancer Foundation; The Women’s Cancer Program (WCP) at the Samuel Oshrin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, is funded by the American Society for Clinical Cancer Research (SP6-05-258-01-COIN).

GEMO Study: National Cancer Genetics Network UNICANCER Genetic Group, France.


Author details
1INSERM U1052, CNRS UMR5286, Université Lyon 1, Centre de Recherche en Cancérologie de Lyon, Lyon, France. 2Université de Lyon, 69000 Lyon, France. 3Université Lyon 1, 69100 Villeurbanne, France. 4UMR CNRS 5558, Laboratoire de Biométrie et Biologie Évolutive (LBBE), “Biométrie et Biologie Évolutive”, Université Claude Bernard Lyon 1, Bâtiment Gélogor Mendel, 1 boulevard du 11 novembre 1918, 69622 Villeurbanne, cedex, France. 5Université Grenoble Alpes, UMR 5217, Laboratoire d’Informatique de Grenoble (LIG), équipe-projet Multi-programmation et Ordonnancement sur ressources pour les Applications Interactives de Simulation (MO AIS), 38041 Grenoble, France. 6INRIA Rhône-Alpes, équipe-projet MOAIS, 38334 Saint Ismier, Cedex, France. 7New York Cancer Genetics Program, Department of Pediatrics, Columbia University College of Physicians and Surgeons, New York, NY, USA. 8Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA. 9Department of Dermatology, University of Utah School of Medicine, Salt Lake City, UT, USA. 10Department of Epidemiology, Cancer Prevention Institute of California, 2201 Walnut Avenue, Suite 300, Fremont, CA 94538, USA. 11Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santariskis Clinics, Vilnius, Lithuania. 12Department of Molecular and Regenerative Medicine, Centre for Innovative Medicine, State Research Institute, Vilnius, Lithuania. 13Latvian Biomedical Research and Study Centre, Rātsupēra iela 1, Riga LV-1067, Latvia. 14Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Shapiro 9, Boston, MA 02215-5400, USA. 15Department of Genetics, University of Pretoria, Private Bag X20, Hatfield, 0028 Pretoria, South Africa. 16Department of Population Sciences, Beckman Research Institute, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA. 17Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 18Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 19Centre for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. 20Human Genetics Group, Spanish National Cancer Research Center (CNIO), Madrid, Spain. 21Center for Biomedical Network Research on Rare Diseases (BERER), Madrid, Spain. 22Medical Oncology Service, Hospital Clínico Universidad Lozano Blesa, Avenida San Juan Bosco, 15, 50009 Zaragoza, Spain. 23Holy Cross Hospital, Michael and Dianne Bienes Comprehensive Cancer Center, Fort Lauderdale, FL, USA. 24Division of Clinical Cancer Genetics, City of Hope (for the Clinical Cancer Genetics Community Research Network), City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA. 25Department of Medical Genetics, Istituto Nazionale dei Tumori (INT), Via Zamboni 65, 20133 Milan, Italy. 26Department of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Istituto di Riposo e Curative, a Carattere Scientifico (IRCCS), Istituto Nazionale dei Tumori (INT), Via Venezian 1, 20133 Milan, Italy. 27Department of Clinical Genetics, Istituto Nazionale di Ricerca per lo Studio e la Cura dei Tumori (INRST), Via Francesco Giordano Bruno 42, 00185 Rome, Italy. 28Department of Hematology, Oncology and Transfusion Medicine, University Hospital Zurich, Zurich, Switzerland. 29Department of Medical Genetics, Institute of Molecular Bases of Genetic Risk and Genetic Testing, Istituto Nazionale dei Tumori (INT), Via @VENZIAN 1, 20133 Milan, Italy.

Prevention and Special Functions, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Azienda Ospedaliera Universitaria “San Martino” di Genova, IST Istituto Nazionale per la Ricerca sul Cancro, Largo Rosanna Benzi, 10, 16132 Genoa, Italy. 40FiorGen Foundation for Pharmacogenomics, Via Luigi Sacconi 6, 50019 Sesto Fiorentino, Italy. 41Unit of Medical Genetics, Department of Biomedical, Experimental and Clinical Sciences of Florence, Florence, Italy. 42Department of Molecular Medicine, Sapienza University, Rome, Italy. 43Department of Medical Oncology, Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece. 44Molecular Diagnostics Laboratory, INRATES, National Centre for Scientific Research “Demokritos”, Aghia Paraskevi Attikis, Athens, Greece. 45Panana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA. 46Molecular Genetics of Breast Cancer, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany. 47Clinical Genetics Department, St Michael’s Hospital, Southwell Street, Bristol BS2 8EG, UK. 48North West Thames Regional Genetics Service, Kennedy-Galton Centre, Harrow, UK. 49Department of Clinical Genetics, Royal Devon & Exeter Hospital, Barrack Road, Exeter EX2 5DW, UK. 50Nenesyide and Cheshire Clinical Genetics Service, Liverpool Women’s NHS Foundation Trust, Walton Hospital, Prescot, L34 1LQ, UK. 51Department of Medical Genetics, Manchester Academic Health Sciences Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK. 52Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Worts Causeway, Cambridge CB1 8RN, UK. 53Institute of Molecular Genetics, National Research Council, Rome, Italy. 54Maze Pond, London SE1 9RT, UK. 55Department of Clinical Genetics, University Hospitals NHS Trust, Maastricht, the Netherlands. 56Institute of Genetics, Centre Léon Bérard, 28 rue Laennec, 69008 Lyon, France. 57Centre Hospitalier Universitaire de Grenoble, CS 10217, 38043, Grenoble cedex 9, France. 58Institut Albert Bonniot – Inserm U823, Université Joseph Fourier, Rond-point de la Chaux, 38051, South Auvergne, France. 59Laboratoire d’Oncogénétique, Hôpital René Huguenin, Institut Curie, 35 rue Daily, 92210 Saint-Cloud, France. 60Department d’Oncogénétique, Centre Jean Perrin, Université de Clermont-Ferrand, 58 rue Montalet, BP 392, 63011 Clermont-Ferrand, France. 61Gynaecological Oncology, Sydney Cancer Centre, Royal Prince Alfred Hospital and University of Sydney, Missenden Road, Camperdown, NSW 2050, Australia. 62Gynecologic Oncology Group, Department of OB/GYN, University of North Carolina at Chapel Hill, 103B Physicians’ Office Building, CB 7572, Chapel Hill, NC 27599-7572, USA. 63Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263-0001, USA. 64Women & Infants Hospital, 1 Blackstone Place, Providence, RI 02905, USA. 65Molecular Oncology Laboratory, Health Research Institute of the San Carlos Clinical Hospital (IDISCI), 28040 Madrid, Spain. 66Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, Biomedical Helsinki, PO Box 700, 00209 Helsinki, Finland. 67Department of Clinical Genetics, Helsinki University Central Hospital, Biomedicum Helsinki 1, Haartmaninkatu 8, 00290 Helsinki, Finland. 68Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, PO Box: 2040, 3000 CA, Rotterdam, the Netherlands. 69Department of Clinical Genetics; Family Cancer Clinic, Erasmus University Medical Center, Rotterdam, the Netherlands. 70Department of Human Genetics, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands. 71Department of Clinical Genetics, Academic Medical Center, Amsterdam, the Netherlands. 72Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands. 73Family Cancer Clinic, Netherlands Cancer Institute, Amsterdam, the Netherlands. 74Department of Clinical Genetics, VU University Medical Center Amsterdam, De Boelelaan 1118, 1081 HV Amsterdam, the Netherlands. 75Department of Genetics, University Medical Center, Groningen, the Netherlands. 76Department of Clinical Genetics, Maastricht University Medical Center, Maastricht, the Netherlands. 77Department of Human Genetics, Center for Human and Clinical Genetics, Leiden University Medical Center, 2300 RC Leiden, the Netherlands. 78Department of Pathology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, the Netherlands. 79Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands. 80Department of Molecular Genetics, National Institute of Oncology, Róth György u 7-9, PO Box 1525 Budapest Pf 21112 Budapest, Hungary. 81Oncogenetics Group, Vatt e Hébron Institute of Oncology (VHIO). University Hospital Vall d’Hebron, Vall d’Hebron Research Institute (VHIR) and Universitat Autònoma de Barcelona, Passeig de la Vall d’Hebron 119, 08035 Barcelona, Spain. 82Genetic Counseling Unit, Hereditary Cancer Program, Institut d‘Investigació Biomèdica de Bellvitge (IDIBELL)-Catalan Institute of Oncology, Hospital Duran i Reynals, 3a planta - Gran Via de l’Hospitalet, 199, 08908 Hospital de Llobregat, Barcelona, Spain. 83Molecular Diagnostic Unit, Hereditary Cancer Program, Institut d‘Investigació Biomèdica de Bellvitge (IDIBELL)-Catalan Institute of Oncology, Hospital Duran i Reynals, 3a planta - Gran Via de l’Hospitalet, 199, 08908 Hospital de Llobregat, Barcelona, Spain. 84Center of Molecular Genetics and Pathomorphology, Faculty of Medicine and Dentistry, Pomeranian Medical
University, al Powstancow Wlkp 72, 70-111 Szczecin, Poland. 148. Lund University Hospital, National Hospital and University of Lund, Medical School, Laboratory of Gastroenterology, Lund University Hospital, DJurek, Iceland. 149. Laboratory of diagnostic genetiğ and Service d’Onco-hématologie, Les Hopitaux Universitaire de Strasbourg, Nouvel Hôpital Civil, 1 place de l’Hôpital, BP 426, 67091 Strasbourg, France. 150. Department of Surgical Sciences, Oncology and Gastroenterology, Padua University, Clinical Surgery II, via Giustina 2, 35124 Padua, Italy. 151. Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto (IOV) – Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), via Gattamelata 64, 35128 Padua, Italy. 152. Department of Genetics, Portuguese Oncology Institute (IPO-PORTEO), Edificio dos Laboratorios, piso 6, 4200-072 Porto, Portugal. 153. Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua de Jorge Vitoria Ferreira 228, 4050-313 Porto, Portugal. 154. Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, 546 Pine Avenue West, Montreal, QC H3W 156, Canada. 155. Department of Health Sciences Research, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 156. Department of Health Sciences Research, Mayo Clinic, 13400 East Shea Boulevard, Scottsdale, AZ 85259, USA. 157. Laboratory of Molecular Genetics, The Danish Cancer Society, 620 University Avenue, Toronto, ON M5S 1A8, Canada. 158. Department of Molecular Genetics, University of Texas MD Anderson Cancer Center, NOR-4435, Los Angeles, CA 90089-9175, USA. 159. Department of Medicine, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 750, Philadelphia, PA 19104-3309, USA. 160. Department of Epidemiology and Biostatistics, Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, 3535 Market Street, Suite 750, Philadelphia, PA 19104-3309, USA. 161. Division of Cancer Medicine, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Unit 1354, PO Box 301439, Houston, TX 77230-1439, USA. 162. Sir Peter MacCallum Department of Oncology, Familial Cancer Centre, Peter MacCallum Cancer Centre, level 3, 5 St Andrews Place, East Melbourne, VIC 3002, Australia. 163. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Level 5, 161 Barry Street, Parkville 3010 VIC, Australia. 164. Women’s Cancer Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. 165.Service de génétique oncotique, Institut Curie, Inserm U830, 26 rue d’Ulm, 75248 Paris, France. 166. Faculté de Médecine, Université Paris Descartes, Sorbonne Paris Cité, 15 rue de l’Hôpital, 75006 Paris, France. 167.Génétique médicale, Faculté de Médecine Lyon Est, Université Claude Bernard Lyon 1, 8 avenue Rockefeller, 69373 Lyon, Cedex 08, France. 168.Institut National du Cancer (INCa), La Fondation Synergie Lyon Cancer, Centre Léon Bérard, 28 rue Lainein, 69008 Lyon, Cedex 08, France. 169.Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. 170. Department of Cancer Epidemiology, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA. 171.Unité Mixte de Génétique Constitutionnelle des Cancers Fréquents, Hospices Civils de Lyon – Centre Léon Bérard, 69373 Lyon, Cedex 08, France. 172. Clinical Cancer Genetics Community Research Network, City of Hope, 1500 East Duarte Road, Duarte, CA 91010, USA. Received: 17 September 2014 Accepted: 27 March 2015

Published online: 25 April 2015

References